Propoxyphene Napsylate and Acetaminophen Tablets
... Blood gases, pH, and electrolytes should be monitored in order that acidosis and any electrolyte disturbance present may be corrected promptly. Acidosis, hypoxia, and generalized CNS depression predispose to the development of cardiac arrhythmias. Ventricular fibrillation or cardiac arrest may occur ...
... Blood gases, pH, and electrolytes should be monitored in order that acidosis and any electrolyte disturbance present may be corrected promptly. Acidosis, hypoxia, and generalized CNS depression predispose to the development of cardiac arrhythmias. Ventricular fibrillation or cardiac arrest may occur ...
alertec - Shire Canada
... underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating ALERTEC. If ALERTEC is used adjunctively with CPAP, the encouragement of, and periodic ...
... underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating ALERTEC. If ALERTEC is used adjunctively with CPAP, the encouragement of, and periodic ...
opioid codrugs for pain management - UKnowledge
... Pain is an unpleasant sensory and emotional experience associated with actual or potential tissus damage or described in terms of such damage. Opioids are effective in treating moderate to severe pain, but opioid alone therapy is associated with several adverse effects, development of tolerance and ...
... Pain is an unpleasant sensory and emotional experience associated with actual or potential tissus damage or described in terms of such damage. Opioids are effective in treating moderate to severe pain, but opioid alone therapy is associated with several adverse effects, development of tolerance and ...
ACETYLCYSTEINE Solution, USP
... In a teratology study of acetylcysteine in the rabbit, oral doses of 500 mg/kg/day (2.6 times the human mucolytic dose) were administered to pregnant does by intubation on days 6 through 16 of gestation. Acetylcysteine was found to be nonteratogenic under the conditions of study. In the rabbit, two ...
... In a teratology study of acetylcysteine in the rabbit, oral doses of 500 mg/kg/day (2.6 times the human mucolytic dose) were administered to pregnant does by intubation on days 6 through 16 of gestation. Acetylcysteine was found to be nonteratogenic under the conditions of study. In the rabbit, two ...
Médecins sans Frontières application - WHO archives
... doxycycline 100mg orally, twice daily for 7 days (recommended) amoxycillin 500mg orally, 3 times daily for 7 days (alternative) erythromycin 500mg orally, 4 times daily for 7 days (alternative) ofloxacin 300mg orally twice daily, for 7 days (alternative) tetracycline 500mg orally, four times daily f ...
... doxycycline 100mg orally, twice daily for 7 days (recommended) amoxycillin 500mg orally, 3 times daily for 7 days (alternative) erythromycin 500mg orally, 4 times daily for 7 days (alternative) ofloxacin 300mg orally twice daily, for 7 days (alternative) tetracycline 500mg orally, four times daily f ...
aerius kids
... values for desloratadine by 29% and 21% respectively, and 3-hydroxy desloratadine Cmax and AUC values by 77% and 110%, respectively. Erythromycin co-administered with desloratadine increased the Cmax and AUC values for desloratadine by 24% and 14%, respectively. The increases were 43% and 40%, respe ...
... values for desloratadine by 29% and 21% respectively, and 3-hydroxy desloratadine Cmax and AUC values by 77% and 110%, respectively. Erythromycin co-administered with desloratadine increased the Cmax and AUC values for desloratadine by 24% and 14%, respectively. The increases were 43% and 40%, respe ...
Product Monograph for Triumeq
... NEVER restart TRIUMEQ™ or any other abacavir- or dolutegravir-containing product in patients who have stopped therapy with TRIUMEQ™ due to a hypersensitivity reaction. When therapy with TRIUMEQ™ has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation ...
... NEVER restart TRIUMEQ™ or any other abacavir- or dolutegravir-containing product in patients who have stopped therapy with TRIUMEQ™ due to a hypersensitivity reaction. When therapy with TRIUMEQ™ has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation ...
Neomycin - Australian Pesticides and Veterinary Medicines Authority
... Longer intervals between dosing (eg once-daily dosing) that provide a drug-free period in which bacteria are not exposed to the drug appear to preserve bactericidal activity of aminoglycosides and reduce the risk of antimicrobial resistance, as well as toxicity (Freeman et al. 1997). Studies in anim ...
... Longer intervals between dosing (eg once-daily dosing) that provide a drug-free period in which bacteria are not exposed to the drug appear to preserve bactericidal activity of aminoglycosides and reduce the risk of antimicrobial resistance, as well as toxicity (Freeman et al. 1997). Studies in anim ...
panadol osteo data sheet
... paracetamol. Fluctuations in the peak and trough values for plasma paracetamol concentrations were significantly smaller for PANADOL OSTEO than for standard immediate release paracetamol (mean fluctuation index = 0.957 and 1.388, respectively, p<0.001). Consequently, PANADOL OSTEO provided more cons ...
... paracetamol. Fluctuations in the peak and trough values for plasma paracetamol concentrations were significantly smaller for PANADOL OSTEO than for standard immediate release paracetamol (mean fluctuation index = 0.957 and 1.388, respectively, p<0.001). Consequently, PANADOL OSTEO provided more cons ...
concerta - Janssen
... social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program CONCERTA® is indicated as an integral par ...
... social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program CONCERTA® is indicated as an integral par ...
intravenous buprenorphine in humans
... about one half of control values. Walsh et al.28 reported a small decrease in respiratory rate that appeared to plateau as the sublingual dose of buprenorphine was increased to 32 mg. However, after subcutaneous administration of doses up to 8 mg, decreases in respiratory rate were not reported.° Ou ...
... about one half of control values. Walsh et al.28 reported a small decrease in respiratory rate that appeared to plateau as the sublingual dose of buprenorphine was increased to 32 mg. However, after subcutaneous administration of doses up to 8 mg, decreases in respiratory rate were not reported.° Ou ...
data sheet
... metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenyl-5 –methypyrrolidine is inactive, All metabolites are excreted in the faeces and urine together with unchanged methadone. Other metabolites, including methanol and nor-methadol (reported to be pharmacologically active), have also been described, but a ...
... metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenyl-5 –methypyrrolidine is inactive, All metabolites are excreted in the faeces and urine together with unchanged methadone. Other metabolites, including methanol and nor-methadol (reported to be pharmacologically active), have also been described, but a ...
7 Antifungal therapy c h a P t e r
... speed with which the search for effective and safe antifungal agents was progressing.12,13 The introduction of oral griseofulvin and topical chlormidazole in 1958 and the subsequent introduction of IV AmB in 1960 heralded the beginning of the modern era of antifungal therapy.4 Unfortunately, after t ...
... speed with which the search for effective and safe antifungal agents was progressing.12,13 The introduction of oral griseofulvin and topical chlormidazole in 1958 and the subsequent introduction of IV AmB in 1960 heralded the beginning of the modern era of antifungal therapy.4 Unfortunately, after t ...
diltiazem hydrochloride injection
... significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to ...
... significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to ...
PrZOFRAN® Tablets, Oral Solution and Injection PrZOFRAN® ODT
... system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ...
... system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). Hepatic/Biliary/Pancreatic There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ...
acris combi
... prior to breakfast or 2 hours after dinner reduces absorption of risedronate by 55% compared to administration in the fasting state (ie., no food or beverages for 10 hours prior to, or 4 hours after, dosing), and administration one hour prior to breakfast reduces absorption by 30%, risedronate has b ...
... prior to breakfast or 2 hours after dinner reduces absorption of risedronate by 55% compared to administration in the fasting state (ie., no food or beverages for 10 hours prior to, or 4 hours after, dosing), and administration one hour prior to breakfast reduces absorption by 30%, risedronate has b ...
The safety of nebulization with 3 to 5 ml of adrenaline (1:1000) in
... Summary of the findings: Seven clinical trials with a total of 238 patients were included for this review. Two of the five trials in which larger dosages (> 3 ml) of adrenaline were used demonstrated a significant increase in heart rate. The mean increase in heart rate varied from seven to 21 beats ...
... Summary of the findings: Seven clinical trials with a total of 238 patients were included for this review. Two of the five trials in which larger dosages (> 3 ml) of adrenaline were used demonstrated a significant increase in heart rate. The mean increase in heart rate varied from seven to 21 beats ...
Ritalin LA
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
Ritalin LA - Novartis Pharmaceuticals Corporation
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
... Renal Insufficiency: Ritalin LA has not been studied in renally-impaired patients. Renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate since less than 1% of a radiolabeled dose is excreted in the urine as unchanged compound, and the major metabolite (rit ...
Ketorolac Tromethamine Injection, USP (IV/IM) (30 mg/mL)
... allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS – Anaphylactoid Reactions, and PRECAUTIONS – Pre-existing Asthma). Ketorolac tromethamine is contraindicated as prophylactic ana ...
... allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS – Anaphylactoid Reactions, and PRECAUTIONS – Pre-existing Asthma). Ketorolac tromethamine is contraindicated as prophylactic ana ...
Full Prescribing Information
... dose of 100 mg, urine concentrations of trimethoprim ranged from 30 to 160 mcg/mL during the 0- to 4-hour period and declined to approximately 18 to 91 mcg/mL during the 8- to 24-hour period. A 200 mg single oral dose will result in trimethoprim urine concentrations approximately twice as high. Afte ...
... dose of 100 mg, urine concentrations of trimethoprim ranged from 30 to 160 mcg/mL during the 0- to 4-hour period and declined to approximately 18 to 91 mcg/mL during the 8- to 24-hour period. A 200 mg single oral dose will result in trimethoprim urine concentrations approximately twice as high. Afte ...
Flovent - GlaxoSmithKline
... There are limited data from an observational epidemiological study with flucticasone propionate in pregnant women. Results from a retrospective epidemiological study, based on the UK General Practice Research Database (GPRD), did not find an increased risk of major congenital malformations following ...
... There are limited data from an observational epidemiological study with flucticasone propionate in pregnant women. Results from a retrospective epidemiological study, based on the UK General Practice Research Database (GPRD), did not find an increased risk of major congenital malformations following ...
plavix* data sheet
... progressively and reached steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. Platelet aggregation and bleeding time gradually returned to baseline values, generally within 7 days after treatment was disco ...
... progressively and reached steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. Platelet aggregation and bleeding time gradually returned to baseline values, generally within 7 days after treatment was disco ...
product monograph - Takeda Canada Inc.
... The daily dose in patients with severe liver disease should, as a rule, not exceed 20 mg pantoprazole. In severe hepatically impaired patients with Zollinger-Ellison syndrome, doses of pantoprazole should be adjusted according to acid output measurements, and kept at a minimum effective dose. See AC ...
... The daily dose in patients with severe liver disease should, as a rule, not exceed 20 mg pantoprazole. In severe hepatically impaired patients with Zollinger-Ellison syndrome, doses of pantoprazole should be adjusted according to acid output measurements, and kept at a minimum effective dose. See AC ...
risperdal consta
... A lower initial dose of 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with hepatic or renal impairment, for certain drug interactions that increase risperidone plasma concentrations [see Drug Interactions (7.11)] or in patients who have a history of po ...
... A lower initial dose of 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with hepatic or renal impairment, for certain drug interactions that increase risperidone plasma concentrations [see Drug Interactions (7.11)] or in patients who have a history of po ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.